

## Publications 2010-2012

Title	Authors	Journal
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.	Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.	Antimicrob Agents Chemother. 2012 Oct 31
Optimizing Micafungin Dosing in Children.	Zhao W, Hope WW, Manzoni P, Jacqz-Aigrain E.	Pediatr Infect Dis J. 2012 Nov;31(11):1211-1212.
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.	Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA.	Antimicrob Agents Chemother. 2012 Oct;56(10):5303-8.
Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality.	Felton TW, Roberts SA, Isalska B, Brennan S, Philips A, Whiteside S, Doran HM, Leonard C, Al-Aloul M, Yonan N, Hope WW.	J Infect. 2012 Oct;65(4):350-6.
Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an In Vitro Model of Invasive Pulmonary Aspergillosis.	Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.	Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5.
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.	Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.	J Infect Dis. 2012 Aug 1;206(3):442-52.
Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.	Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW.	Antimicrob Agents Chemother. 2012 Aug;56(8):4146-53.
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.	Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.	Antimicrob Agents Chemother. 2012 Aug;56(8):4087-94
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).	Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, <b>Hope W</b> ; EUCAST-AFST.	Clin Microbiol Infect. 2012 Jul;18(7):E246-7.
EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.	Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW; European Committee on Antimicrobial	Clin Microbiol Infect. 2012 Jul;18(7):E248-50.

	Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST).	
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.	Alastruey-Izquierdo A, Gómez-López A, Arendrup MC, Lass-Flörl C, Hope WW, Perlin DS, Rodríguez-Tudela JL, Cuenca-Estrella M.	J Clin Microbiol. 2012 Jul;50(7):2509-12.
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.	Livermore J, <b>Hope W</b> .	Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):759-65.
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against <i>Candida glabrata</i> isolates with and without FKS resistance mutations.	Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, <b>Hope W</b> .	Antimicrob Agents Chemother. 2012 May;56(5):2435-42.
In vitro model of invasive pulmonary aspergillosis in the human alveolus.	Gregson L, Hope WW, Howard SJ.	Methods Mol Biol. 2012;845:361-7.
Posaconazole: the case for therapeutic drug monitoring.	Howard SJ, Felton TW, Gomez-Lopez A, Hope WW.	Ther Drug Monit. 2012 Feb;34(1):72-6.
Anidulafungin for neonatal hematogenous <i>Candida</i> meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.	Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowicz M, Walsh TJ, Benjamin DK Jr, Hope WW.	Antimicrob Agents Chemother. 2012 Feb;56(2):708-14.
Population pharmacokinetics of voriconazole in adults.	Hope WW.	Antimicrob Agents Chemother. 2012 Jan;56(1):526-31
EUCAST technical note on Amphotericin B.	Lass-Flörl C, Arendrup MC, Rodríguez-Tudela JL, Cuenca-Estrella M, Donnelly P, <b>Hope W</b> ; European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing.	Clin Microbiol Infect. 2011 Dec;17(12):E27-9.
The management of <i>Candida</i> infections in preterm neonates and the role of micafungin.	Manzoni P, Benjamin DK, <b>Hope W</b> , Rizzollo S, Del Sordo P, Stronati M, Jacqz-Aigrain E, Castagnola E, Farina D.	J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 2:24-7.
EUCAST technical note on posaconazole.	Arendrup MC, Cuenca-Estrella M, Donnelly JP, <b>Hope W</b> , Lass-Flörl C, Rodríguez-Tudela JL; European committee on antimicrobial susceptibility testing - subcommittee on antifungal susceptibility testing (EUCAST-AFST).	Clin Microbiol Infect. 2011 Nov;17(11):E16-7.
EUCAST technical note on anidulafungin.	Arendrup MC, Rodríguez-Tudela JL, Lass-Flörl C, Cuenca-Estrella M, Donnelly JP, <b>Hope W</b> ; European committee on antimicrobial	Clin Microbiol Infect. 2011 Nov;17(11):E18-20

	susceptibility testing - subcommittee on antifungal susceptibility testing (EUCAST-AFST)	
Pharmacodynamics of echinocandins against <i>Candida glabrata</i> : requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.	Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.	Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.	Troke PF, Hockey HP, Hope WW.	Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8.
Disseminated Candidiasis caused by <i>Candida albicans</i> with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.	Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.	Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83.
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.	Cohen-Wolkowicz M, Benjamin DK Jr, Piper L, Cheifetz IM, Moran C, Liu P, Aram J, Kashuba AD, Capparelli E, Walsh TJ, Hope WW, Smith PB.	Clin Pharmacol Ther. 2011 May;89(5):702-7.
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.	Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW.	J Infect Dis. 2011 May 1;203(9):1324-32.
Optimizing management of invasive mould diseases.	Agrawal S, <b>Hope W</b> , Sinkó J, Kibbler C.	J Antimicrob Chemother. 2011 Jan;66 Suppl 1:i45-53
Fluconazole loading dose pharmacokinetics and safety in infants.	Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, Wade KC, Cohen-Wolkowicz M, Benjamin DK Jr.	Pediatr Infect Dis J. 2011 May;30(5):375-8.
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.	Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW.	Clin Infect Dis. 2010 Dec 15;51(12):1383-91
In the initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) $\beta$ -d-glucan and consequences of delayed antifungal therapy.	Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ.	Antimicrob Agents Chemother. 2010 Nov;54(11):4879-86.
Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.	Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW.	Antimicrob Agents Chemother. 2010 Aug;54(8):3432-41

Population pharmacokinetics of micafungin in neonates and young infants.	Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowicz M, Benjamin DK Jr.	Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7.
Therapy for fungal diseases: opportunities and priorities.	Denning DW, Hope WW.	Trends Microbiol. 2010 May;18(5):195-204.
Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?	Roberts JA, Hope WW, Lipman J.	Int J Antimicrob Agents. 2010 May;35(5):419-20.
Safety and pharmacokinetics of repeat-dose micafungin in young infants.	Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ.	Clin Pharmacol Ther. 2010 Jan;87(1):93-9.